Načítá se...
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
B-cell receptor (BCR) signaling is a critical pathway in the pathogenesis of several B-cell malignancies, including chronic lymphocytic leukemia (CLL), and can be targeted by inhibitors of BCR-associated kinases, such as Bruton tyrosine kinase (Btk). PCI-32765, a selective, irreversible Btk inhibito...
Uloženo v:
Vydáno v: | Blood |
---|---|
Hlavní autoři: | , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
American Society of Hematology
2012
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916557/ https://ncbi.nlm.nih.gov/pubmed/22180443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-386417 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|